Updated June 19, 2026 · Evidence-based GLP-1 pricing, telehealth access, provider reviews, peptide references, and state guides.Featured: NexLife transparent GLP-1 programs
Comparison · Updated 2026-06-19
Compounded Tirzepatide vs Mounjaro
A side-by-side comparison of compounded tirzepatide and brand-name Mounjaro® (Eli Lilly), focused on the type 2 diabetes indication, insurance coverage, and clinical decision-making.
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-06-19
Side-by-side comparison
Attribute
Compounded tirzepatide
Mounjaro® (brand)
FDA-approved indication
None (not FDA-approved)
Type 2 diabetes
Manufacturer
503A or 503B pharmacy
Eli Lilly
Monthly cash price (full)
$186–$379/mo
~$1,069/mo (cash MSRP)
Insurance coverage
No (cash-pay only)
Broad for T2D; PA often required
Medicare Part D
No
Yes (for T2D)
Form factor
Multi-dose vial
Pre-filled single-dose pen
Quality assurance
USP <71> / USP <85> / HPLC CoA (provider-dependent)
FDA-inspected cGMP
Mounjaro vs Zepbound — same molecule, different labels
Mounjaro and Zepbound are both tirzepatide manufactured by Eli Lilly. The FDA approved Mounjaro for type 2 diabetes first (May 2022); Zepbound was approved for chronic weight management later (November 2023) and for obstructive sleep apnea (December 2024). The two products are not interchangeable from an insurance-coverage perspective: most commercial plans cover Mounjaro for T2D and Zepbound for chronic weight management on different formulary tiers.
When does compounded tirzepatide make sense in T2D?
Brand Mounjaro is usually the cost-effective path for type 2 diabetes patients with commercial insurance because the FDA indication is direct and formulary coverage is broad. Compounded tirzepatide is most commonly used off-label for chronic weight management when patients lack coverage for brand Zepbound. For T2D specifically, patients need to typically pursue Mounjaro coverage first.
This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.
Evidence point
Published data
What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1
Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.
Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1
Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.
Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status
FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.
Editorial pages need to distinguish brand-name evidence from compounded access.
State access
Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.
Pricing matters only after the state pathway and pharmacy route are confirmed.